Prostate Cancer: Epidemiology and Screening

Overview

Journal Rev Urol

Date 2006 Sep 21

PMID 16986040

Citations 5

Authors

M K Brawer

E D Crawford

J Fowler

M S Lucia

F H Schroeder

Affiliations

Soon will be listed here.

Abstract

The challenge continues-to find better methods of screening for prostate cancer, of determining who should undergo needle biopsy, and of predicting who will fail initial therapy. Investigators are looking at the value of neural networks and an array of markers to provide improved screening and prognostic information.

Citing Articles

Comparative Serum Proteome Profiling of Canine Benign Prostatic Hyperplasia before and after Castration.

Ploypetch S, Wongbandue G, Roytrakul S, Phaonakrop N, Prapaiwan N Animals (Basel). 2023; 13(24).

PMID: 38136890 PMC: 10740436. DOI: 10.3390/ani13243853.

Gleason score and tumor laterality in radical prostatectomy and transrectal ultrasound-guided biopsy of the prostate: a comparative study.

Pereira R, Costa R, Muglia V, Silva F, Lajes J, Reis R Asian J Androl. 2015; 17(5):815-20.

PMID: 25652629 PMC: 4577597. DOI: 10.4103/1008-682X.146970.

Cyclin D1 expression in prostate carcinoma.

Pereira R, Ravinal R, Costa R, Lima M, Tucci S, Muglia V Braz J Med Biol Res. 2014; 47(6):515-21.

PMID: 24820071 PMC: 4086179. DOI: 10.1590/1414-431x20143240.

Potential clinical importance of the activation peptide of prostate-specific antigen.

Voeghtly L, Thogersen I, Valnickova Z, Sanggaard K, Chu C, Oury T Int J Clin Exp Pathol. 2009; 2(6):588-98.

PMID: 19636406 PMC: 2713450.

Management of complications of androgen deprivation therapy in the older man.

Mohile S, Mustian K, Bylow K, Hall W, Dale W Crit Rev Oncol Hematol. 2008; 70(3):235-55.

PMID: 18952456 PMC: 3074615. DOI: 10.1016/j.critrevonc.2008.09.004.

References

Partin A, Kattan M, Subong E, Walsh P, Wojno K, Oesterling J . Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997; 277(18):1445-51. View

Partin A, Yoo J, Carter H, Pearson J, Chan D, Epstein J . The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150(1):110-4. DOI: 10.1016/s0022-5347(17)35410-1. View

Roach 3rd M, KRALL J, Keller J, Perez C, Sause W, Doggett R . The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985). Int J Radiat Oncol Biol Phys. 1992; 24(3):441-9. DOI: 10.1016/0360-3016(92)91058-u. View

Gettman M, Pacelli A, Slezak J, Bergstralh E, Blute M, Zincke H . Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology. 1999; 54(3):479-85. DOI: 10.1016/s0090-4295(99)00202-2. View

Rubin M, Buyyounouski M, Bagiella E, Sharir S, Neugut A, Benson M . Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology. 1999; 53(3):542-7. DOI: 10.1016/s0090-4295(98)00561-5. View

Fowler Jr J, Sanders J, Bigler S, Rigdon J, Kilambi N, Land S . Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml. J Urol. 2001; 163(5):1467-70. View

Cookson M, Fleshner N, Soloway S, Fair W . Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol. 1997; 157(2):559-62. View

Stein A, DeKernion J, Smith R, dOrey F, Patel H . Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol. 1992; 147(3 Pt 2):942-6. DOI: 10.1016/s0022-5347(17)37429-3. View

Bahnson R, Dresner S, Gooding W, Becich M . Incidence and prognostic significance of lymphatic and vascular invasion in radical prostatectomy specimens. Prostate. 1989; 15(2):149-55. DOI: 10.1002/pros.2990150208. View

10.

Epstein J, Walsh P, Carmichael M, Brendler C . Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994; 271(5):368-74. View

11.

Elgamal A, Van Poppel H, Van de Voorde W, Van Dorpe J, Oyen R, Baert L . Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens--a different view. J Urol. 1997; 157(1):244-50. DOI: 10.1016/s0022-5347(01)65337-0. View

12.

McNeal J, Villers A, Redwine E, Freiha F, Stamey T . Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer. 1990; 66(6):1225-33. DOI: 10.1002/1097-0142(19900915)66:6<1225::aid-cncr2820660624>3.0.co;2-x. View

13.

Hoenig D, Chi S, Porter C, Tackett L, Smith D, COHEN S . Risk of nodal metastases at laparoscopic pelvic lymphadenectomy using PSA, Gleason score, and clinical stage in men with localized prostate cancer. J Endourol. 1997; 11(4):263-5. DOI: 10.1089/end.1997.11.263. View

14.

Salomao D, Graham S, Bostwick D . Microvascular invasion in prostate cancer correlates with pathologic stage. Arch Pathol Lab Med. 1995; 119(11):1050-4. View

15.

Crawford E, Hirano D, Werahera P, Lucia M, DeAntoni E, Daneshgari F . Computer modeling of prostate biopsy: tumor size and location--not clinical significance--determine cancer detection. J Urol. 1998; 159(4):1260-4. DOI: 10.1016/s0022-5347(01)63576-6. View

16.

Brawer M, Deering R, Brown M, Preston S, Bigler S . Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer. 1994; 73(3):678-87. DOI: 10.1002/1097-0142(19940201)73:3<678::aid-cncr2820730329>3.0.co;2-6. View

17.

McNeal J . Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol. 1992; 23(3):258-66. DOI: 10.1016/0046-8177(92)90106-d. View

18.

Egawa S, Suyama K, Matsumoto K, Satoh T, Uchida T, Kuwao S . Improved predictability of extracapsular extension and seminal vesicle involvement based on clinical and biopsy findings in prostate cancer in Japanese men. Urology. 1998; 52(3):433-40. DOI: 10.1016/s0090-4295(98)00207-6. View

19.

Vijayakumar S, Karrison T, Weichselbaum R, Chan S, Quadri S, Awan A . Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992; 1(7):541-5. View

20.

Cheng W, Frydenberg M, Bergstralh E, Zincke H . Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology. 1993; 42(3):283-91. DOI: 10.1016/0090-4295(93)90617-j. View